- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07329673
Examen des performances de QbMobile dans le diagnostic différentiel associé aux symptômes du TDAH
Un examen de la performance de QbMobile dans le diagnostic différentiel associé aux symptômes du TDAH.
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This study aims to evaluate the performance of QbMobile in children, adolescents, and adults assessed for and diagnosed with ASD (Autism Spectrum Disorder, MDD (Major Depressive Disorder), Bipolar Disorder, or Anxiety Disorder, or has a prior diagnosis of one of the included disorders but is not currently receiving treatment. Participants will complete the 10-minute QbMobile test on their personal device during a scheduled clinical visit. They will then repeat the test remotely the following day at the same time as the previous test +/-3 hours. Participants will be asked to complete QbMobile prior to initiating any treatment.
Note on Outcome Measures Presentation:
The IRB-approved protocol defines endpoints broadly (e.g., identification of QbMobile domain profiles, classification accuracy, variability, and exploratory analyses). To comply with ClinicalTrials.gov requirements that each outcome measure represent a single assessment with a single unit of measure, these endpoints are operationalized into separate outcome measures corresponding to individual QbMobile metrics (domain SD-scores, Total Score [0-100], accuracy percentages, variability estimates).
This operationalization does not introduce new scientific endpoints or alter study objectives, design, or analyses. It ensures clarity and compliance for registry reporting while maintaining alignment with the approved protocol.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Miami, Florida, États-Unis, 33133
- CCM Clinical Research Group
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Potential study participants who meet the eligibility criteria will be identified through referrals and recruitment efforts at the participating study sites.
La description
Inclusion Criteria:
- Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
- Aged > 6 years and < 60 years old;
- Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment;
- Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures;
- Have adequate sensory and physical ability to complete QbMobile;
- Possess or have access to an iPhone model that supports QbMobile.
Exclusion Criteria:
- Intellectual disability designated by IQ<70;
- Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder;
- Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation);
- Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc);
- Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
- Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance;
- Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
ASD
Eligible participants being referred for their initial assessment or have a diagnosis of ASD but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Bipolar disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Bipolar Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
MDD
Eligible participants being referred for their initial assessment or have a diagnosis of MDD but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Separation Anxiety Disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Separation Anxiety Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Social Anxiety Disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Social Anxiety Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Generalized Anxiety Disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Generalized Anxiety Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Identification of QbMobile Domain Profiles Using SD-Scores and Total Score (0-100)
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels, including attention, impulsivity, activity, and movement patterns. The study will identify statistically distinct QbMobile domain profiles for each diagnostic group (ASD, MDD, Bipolar Disorder, Anxiety Disorder) using domain SD-scores and the QbMobile Total Score (0-100). (Component metrics are listed as secondary outcomes to meet single-measure reporting requirements.) |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
QbMobile Domain SD-Scores (Attention, Impulsivity, Activity, Movement) - Group Differences
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. Domain scores will be analyzed as SD-scores to assess differences among diagnostic groups (ASD, MDD, Bipolar Disorder, Anxiety Disorder). |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
|
QbMobile Total Score (0-100) - Group Differences
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. The Total Score (0-100; higher values indicate greater likelihood of ADHD symptomatology) will be compared across diagnostic groups to assess differences. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
|
Classification Accuracy Using QbMobile Domain SD-Scores
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. Classification accuracy among diagnostic groups will be evaluated using domain SD-scores; metrics will include sensitivity, specificity, and predictive values. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
|
Classification Accuracy Using QbMobile Total Score (0-100)
Délai: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. Classification accuracy among diagnostic groups will be evaluated using the Total Score; metrics will include sensitivity, specificity, and predictive values based on prespecified thresholds. |
QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2)
|
|
Comparison of QbMobile Domain SD-Scores with Normative Dataset
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Domain SD-scores will be compared with the age- and sex-adjusted normative dataset to identify differences between diagnostic groups and normative patterns. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
|
Comparison of QbMobile Total Score (0-100) with Normative Distribution
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Total Scores will be compared with the normative distribution to identify deviations from expected values. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
|
Variability in Differentiation Using QbMobile Domain SD-Scores
Délai: Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Variability in group differentiation will be assessed using domain SD-scores (e.g., confidence intervals and variance estimates across repeated measures). |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
|
Variability in Differentiation Using QbMobile Total Score (0-100)
Délai: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Variability will be assessed using Total Scores (e.g., confidence intervals and variance estimates across repeated measures). |
QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
|
Exploratory Analysis of Additional QbMobile Domain Parameters (SD-Based)
Délai: QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
Consistent with the protocol statement that "all data collected from QbMobile during this study will be available to explore additional domain parameters," exploratory analyses will examine QbMobile domain data using SD-based metrics to identify additional parameters for further analysis. |
QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
|
Exploratory Analysis of Additional QbMobile Parameters from Total Score and Raw Performance Data
Délai: Visit 1 (clinic) and Visit 2 (remote, next day).
|
Consistent with the protocol statement that "all data collected from QbMobile… will be available to explore additional domain parameters," exploratory analyses will use the QbMobile Total Score (0-100) and raw performance data (e.g., response time, error counts, movement traces) to identify additional parameters for further analysis. |
Visit 1 (clinic) and Visit 2 (remote, next day).
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles bipolaires et apparentés
- Les troubles mentaux
- Troubles de l'humeur
- Troubles neurodéveloppementaux
- Troubles envahissants du développement de l'enfant
- Troubles phobiques
- Troubles anxieux
- Troubles du spectre autistique
- Phobie sociale
- Trouble bipolaire
- Anxiété, Séparation
- Désordre anxieux généralisé
Autres numéros d'identification d'étude
- Pro00090568 QB25-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Due to the nature of the research, limited access to supporting data may be granted upon reasonable request under confidentiality agreements from the corresponding sponsor.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .